CLDX

Celldex Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-25

Figures on this page computed 2026-11-08 12:48 UTC

Last close

29.87USD

Market data, 2026-11-06

CLDX: weekly closes from 41.95 on 2026-08-14 to 29.87 on 2026-11-06, a move of -28.8%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-06

Over that span: -28.8%

Except where said otherwise: 10-K for 2025, filed 2026-02-25

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
-57.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
-16748.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
-13829.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
0.004Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.12 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.25x

2.11x

2.07x

1.02x

1.10x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-25

Sales0.25x
Its own average over 10 years, 6.3M.
Profit2.11x
Its own average over 10 years, -122.4M.
Free cash flow2.07x
Its own average over 10 years, -103.3M.
Debt1.02x
Its own average over 10 years, 2.3M.
Price1.10x
Its own average over 11 years, 27. Market data, 2026-11-06

Profit is furthest from its own average, at 2.11 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	187.8	n/a
2018-12-31	140.6	n/a
2019-12-31	52.7	100.0
2020-12-31	109.3	204.3
2021-12-31	68.5	295.5
2022-12-31	34.7	323.2
2023-12-31	101.4	333,969.8
2024-12-31	103.4	443,889.2
2025-12-31	22.8	457,861.7

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001104659-26-019652
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001104659-26-019652
Reported in: USD

The filing itself

Figures behind the shape

Growth

-26.9%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-26.9%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-63.9%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-57.4%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital-57.4%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on equity-49.1%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on assets-44.4%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself

Margins

87.1%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin87.1%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Operating margin-18599.8%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Net margin-16748.0%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Free cash flow margin-13829.1%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself

Price

3.8x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
Price to book3.8x10-Q for 2025, filed 2026-08-06
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001104659-26-091984
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-06
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-25
The filing itself
Price to sales ratio1284.2x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself

Safety

0.004

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.004
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
The filing itself
Current ratio10.4910-Q for 2025, filed 2026-08-06
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001104659-26-091984
Reported in
USD
- 10-Q for 2025, filed 2026-08-06
- 10-Q for 2025, filed 2026-08-06
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Altman Z-Score16.34
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001104659-26-019652
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.